Teva, Department of Justice Agree to Drug Price Fixing Settlement
Pharma company to pay a fine of $225 million over five years.
Teva Pharmaceuticals and the Department of Justice (DOJ) have agreed to terms on a deferred prosecution agreement (DPA) regarding criminal price-fixing charges first brought against the company in 2020. The agreement, which allows Teva to avoid exclusion from participation in US federal health care programs, includes a fine of $225 million over the next five years. The organization also agreed to donate approximately $50 million worth of two generic products (valued at wholesale acquisition cost), to humanitarian organizations, and to divest one additional generic product to a third-party buyer.
In a company press release, Teva admitted that a former employee agreed with competitors that Teva would not bid on an opportunity to supply a customer with a particular generic product.
Reference: Teva Settles Price Fixing Charges With U.S. DOJ. Teva. August 21, 2023. Accessed August 24, 2023. https://www.tevapharm.com/news-and-media/latest-news/teva-settles-price-fixing-charges-with-u.s.-doj/
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
